Piper Jaffray Cos. downgraded Alcobra Ltd (NASDAQ:ADHD) to Neutral in a statement released earlier today.
- Updated: September 29, 2016
Piper Jaffray Cos. has downgraded Alcobra Ltd (NASDAQ:ADHD) to Neutral in a statement released on 9/29/2016.
Previously on 09/12/2016, WBB Securities reported about Alcobra Ltd (NASDAQ:ADHD) lowered the target price from $5.00 to $4.00 that suggested a downside of -0.17%.
Yesterday Alcobra Ltd (NASDAQ:ADHD) traded -53.64% lower at $2.03. Alcobra Ltd’s 50-day moving average is $4.83 and its 200-day moving average is $4.53. The last stock close price is down -52.77% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 1,624,270 shares of Alcobra Ltd traded, up from an avg. volume of 92,709
Alcobra Ltd has 52 week low of $2.00 and a 52 week high of $8.78 and has a total market value of $0.
A total of 7 equity analysts have released a research note on ADHD. Three brokerages rating the stock a strong buy, 3 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $12.71.
General Company Details For Alcobra Ltd (NASDAQ:ADHD)
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse. MG01CI product has completed phase two studies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.